GenSight Sees Positives In Pivotal RESCUE Trial, Despite Missing Primary Endpoint

The company's gene therapy didn't hit the primary endpoints in either of its two Phase III studies in a severe genetic retinal disease reported so far, but a third trial designed through a special protocol assessment with the US FDA is ongoing.